Angeles Mencia Rodriguez

CIEMAT, Madrid

Genome editing for genodermatoses therapy: correction of a Netherton syndrome patient´s cells carrying a deep intronic pathogenic variation.

Mercedes Dessy Rodríguez

CIEMAT, Madrid

Correction of congenital dyserythropoietic anemia type II using lentiviral gene therapy

Angel Fernandez-Ramirez

UNICA, Hospital Universitario 12 de Octubre, Madrid

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies

Berta Marzal-Marti

Idibaps Barcelona

Preclinical development of low-affinity HER2-specific CAR-T cells for the treatment of HER2+ breast cancer

Guillermo Güenechea Amurrio

CIEMAT, CIBERER, Madrid

Editing of Telomerase RNA Component gene in hematopoietic stem cells: An alternative tool to treat bone marrow failure in patients with autosomal dominant dyskeratosis congenita

Isabel Ojeda-Perez

CIEMAT, CIBERER, Mardid

Studying Hematopoietic Stem Cell clonality in Gene Editing Strategies using DNA Barcoding

Ignacio Perez de Castro

Instituto de Salud Carlos III, Madrid

CRISPR-based strategies revert the LMNAᴿ²⁴⁹ᵂ induced phenotype both in cultured cells and in vivo

Noelia Maldonado Pérez

GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia

Feasibility of generating universal ARI-0001 T cells for the treatment of type B malignances

D Sanchez-Martinez

Josep Carreras Leukemia Research Institute; Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III (ISCII) (RICORS, RD21/0017/0029)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia

C Bueno

Josep Carreras Leukemia Research Institute. Campus Clinic. Barcelona. Spain; Centro de Investigación Biomédica en Red en Oncología (CIBER-ONC), ISCIII, Madrid, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain.

CD34⁺CD19⁻CD22⁺ B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed therapies

B Blanco

Instituto de Investigación Hospital 12 de Octubre (i+12); Hospital Universitario 12 de Octubre; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III

Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers

M Tristán-Manzano

LentiStem Biotech

Physiological (TCR-like) regulated lentiviral vectors: a platform for the generation of improved CAR-T cells